Figure 1
From: Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer
Study design. BD, benign disease; CA125, tumor-associated antigens; ELR, enter-logistic regression; ELISA, Enzyme-linked immunosorbent assay; FLR, forward logistic regression; GBM, HE4, human epididymis protein 4; gradient boosting decision tree; NB, Naive Bayes; NC, normal controls; NN, neural network; OC, ovarian cancer; RF, random forest; ROMA, risk of ovarian malignancy algorithm; SVM, support vector machine; TAAbs, anti-tumor-associated antigen autoantibodies.
